Jian Sun

Prof. Jian Sun


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
HZHaodi Zhao
Haodi Zhao
JWJing Wei
Jing Wei
JSJian Sun
Jian Sun

1 July 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
LXLe Xu
Le Xu
XSXiaolei Song
Xiaolei Song
LSLili Su
Lili Su
YZYong Zheng
Yong Zheng
RLRu Li
Ru Li
JSJian Sun
Jian Sun

18 January 2019 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
YWYuehua Wang
Yuehua Wang
Zihua WangZihua Wang
Zihua Wang
YQYixia Qian
Yixia Qian
LFLinyang Fan
Linyang Fan
CYChunyan Yue
Chunyan Yue
WWWeizhi Wang
Weizhi Wang
A synergetic targeted liposomal system which functionalized with both a tumor identification ligand and an immune targeting ligand was constructed. It could recognize and bind ER-positive breast cancer tissues in a specific way and reduce the macrophage phagocytosis of the nanoparticles.

29 May 2020 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
DFDeming Feng
Deming Feng
JSJian Sun
Jian Sun
Multiple myeloma (MM) is a haematological malignancy caused by malignant proliferation of plasma cells in bone marrow. In recent years, MM patients are commonly treated with chemotherapy, autologous stem cell transplantation, protease inhibitors, immunomodulatory drugs and monoclonal antibodies, however most patients eventually relapse. Therefore, more effective therapies are highly needed. Anti‐BCMA CAR‐T therapy, a novel and efficacious method for treating MM and relapsed/refractory multiple myeloma (RRMM), has been designed and applied in clinics. The CAR‐T can specifically recognize the targeted molecule B cell maturation antigen (BCMA) and kill MM cells expressing BCMA and several clinical trials have revealed high response rates in the therapy. Herein, we summarize the developments, the current design and clinical trials, the side effects of anti‐BCMA CAR‐T therapy and comparison of it with other CAR‐T therapies.

1 March 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
ZZZhen Zhao
Zhen Zhao
XZXiaojuan Zhang
Xiaojuan Zhang
LSLili Su
Lili Su
LXLe Xu
Le Xu
YZYong Zheng
Yong Zheng
JSJian Sun
Jian Sun

19 June 2022 in International Immunopharmacology
Verified
Journal Article
Closed access
DJDongfu Jin
Dongfu Jin
YJYaxin Jiang
Yaxin Jiang
LCLu Chang
Lu Chang
JWJing Wei
Jing Wei
JSJian Sun
Jian Sun